Collectively, these findings suggest that pharmacologic inhibition of the PKM2–EIF2AK2 pathway attenuates inflammasome activation and protects mice from lethal endotoxemia and polymicrobial sepsis. This evidence concerns the gene EIF2AK2 and serum lipopolysaccharide activity.